Chronic myelogenous leukemia [CML]; myeloproliferative disorders like severe thrombocytosis and polycythemia vera; an adjunct in the treatment of myelofibrosis; a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for non-malignant diseases.
Usual dose in adult and children: 0.065-0.1 mg/kg daily. It is individualized based on clinical and haematologic response and tolerance of the patient. Consult specialist literature for further information.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
An alkylating agent that interferes with DNA replication and transcription of RNA.
It must be used only under constant supervision by physicians experienced in therapy with cytotoxic agents due to its low therapeutic index; increased incidence of infections; increased incidence of hemorrhagic complications; blood counts should be performed at least once a week.
Chronic myelogenous leukemia resistant to prior therapy with the drug
Its major side effect is haematological toxicity, which include severe leukopenia, anaemia, and severe thrombocytopenia; hyperuricaemia due to increased catabolism; uric acid nephropathy; renal stones; acute renal failure.
Additive myelosuppression with concomitant administration with other myelosuppressive agents